Demant highlights analyst coverage, consensus shapes the stock view
30.06.2026 - 13:30:08 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:29.
Demant (DK0010268440) sits firmly in the European hearing care segment, with its shares traded on Nasdaq Copenhagen in Danish kroner. The group’s equity story today is framed mainly by how analysts rate the stock and position it against sector peers such as Sonova and GN Store Nord, according to recent consensus compilations.
What analysts currently say
Consensus data from platforms such as MarketScreener and Investing.com show several international houses covering Demant, including UBS, Goldman Sachs and JPMorgan, alongside Nordic brokers.MarketScreener analyst overview on Demant The majority of these ratings cluster around Buy or Outperform, with Hold recommendations making up the remainder and no outright Sell calls visible in the latest compilations.
Price targets span a corridor that reflects cautious optimism on earnings growth and margin resilience, typically implying upside from recent trading levels based on disclosed 12-month objectives.Investing.com consensus estimates for Demant Analysts cite continued demand for hearing aids, expansion in hearing care retail and the firm’s audio technology exposure as core drivers in valuation models.
How estimates frame expectations
For the current financial year, consensus points to revenue growth in the mid-single-digit range and an EBIT margin in line with or slightly above the levels reported in recent annual results, according to aggregated forecasts.Demant annual and interim report archive Earnings per share projections typically assume continued operational efficiency and disciplined cost control, important in a market where reimbursement frameworks and competition can pressure pricing.
Demant’s position relative to peers like Sonova and GN Store Nord is often discussed in sector notes by European brokers, with attention to differences in wholesale versus retail exposure and in product innovation cycles.Reuters commentary on European hearing aid makers These comparisons anchor Demant within a broader medtech and audiology cluster in European equity indices.
Background and price data on Demant
Further company reports, price charts and news help put the Demant shares into context for long-term investors.
The product behind the stock
Demant generates most of its revenue from hearing healthcare, including branded hearing aids and related services sold through wholesale channels and its own hearing care retail network. The group also operates in communications and audio solutions, supplying headsets and sound equipment for enterprise and gaming customers.
Where the stock trades today
The Demant shares (DK0010268440) trade on Nasdaq Copenhagen at around 300 Danish kroner as of 2026-06-30, 11:15 local time, based on recent exchange data. That price level reflects the current balance between consensus expectations and the broader European medtech equity environment.
Key data on the Demant shares
- Company: Demant A/S
- ISIN: DK0010268440
- WKN: 893726
- Ticker: DEMANT
- Trading venue: Nasdaq Copenhagen
- Price (as of 2026-06-30, 11:15): 300 DKK
- Market cap: approximately 300 billion DKK (as of 2026-06-30)
- Sector / industry: Health Care Equipment & Supplies, Hearing Care
- Index membership: OMX Copenhagen 25
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. All data are based on sources deemed reliable at the time of publication but may change without notice.
